Proactive Investors - Run By Investors For Investors

Cosmos Holdings welcomes prominent oncologist to advisory board

Dr. Ioannis Dedes is a founding member of the Society of Interventional Oncology
pills
Cosmos is an international pharmaceutical company with offices and distribution centers in Greece and the United Kingdom

Cosmos Holdings Inc (OTCQB:COSM) is bolstering its advisory board with the appointment of Dr. Ioannis Dedes, a prominent radiologist and oncologist.

Dr. Dedes is a founding member of the Society of Interventional Oncology and a director of the Endovascular Interventional Radiology department at the Interbalkan European Medical Center in Thessaloniki, Greece.

READ: Cosmos Holdings focuses on Europe as it expands its global wholesale pharmaceutical business

Cosmos CEO Grigorios Siokas is keen on Dedes’ elevation to the board, citing his healthcare expertise.

“Dr. Ioannis Dedes brings a wealth of experience to our group,” noted Siokas in a statement. “Dr. Dedes’s addition to our board will provide strategic and tactical support to our enterprise healthcare process, as well as our business development.”

Dedes’ appointment follows the recent addition of Anastasios Tzikas, the former CEO of Singular Northern Greece SA, one of Greece’s largest software vendors, to the Cosmos board.

Cosmos is an international pharmaceutical company with offices and distribution centers in Greece and the United Kingdom.

Cosmos shares slipped slightly to close at $6.99 on Tuesday.

Contact Ellen Kelleher at [email protected]

View full COSM profile View Profile

Cosmos Holdings Inc Timeline

Related Articles

scientist at petrie dish
May 15 2019
Here we take a closer look at Midatech Pharma PLC (LON:MTPH)
Enzymes under a microscope
April 28 2019
The Florida company applies its proprietary C1 gene expression platform to speed up the development of biologic vaccines, drugs at flexible commercial scales
cancerous cells
March 08 2019
A series of trials underway at major cancer research hospitals are evaluating the company's flagship cancer drug Ampligen
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use